PRODUCTS SOLD BY ASCEND PEPTIDES ARE INTENDED FOR RESEARCH USE ONLY.
Laboratory research material
Sermorelin 5mg research peptide UK is the 5mg format of sermorelin (GRF 1-29 NH2), the unmodified 29-amino-acid GHRH fragment, for laboratory programmes requiring larger compound quantities. Janoshik report published for a tested batch. Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri). For research use only.
Research guides: Sermorelin research guide · GHRH analogues vs GHRPs
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
SERMORELIN 5mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Sermorelin 5 mg:
View Janoshik report #125393 (tested sample: Sermorelin 5mg)
This report covers one tested sample. It does not establish that current stock comes from the same batch.
Sermorelin 5mg Research Peptide UK
Sermorelin 5mg is the larger-format version of Sermorelin 2mg. Identical compound to Sermorelin 2mg — C149H246N44O42S, 3,357.93 Da, GRF 1-29 NH2, unmodified 29-amino acid GHRH sequence — supplied in a larger quantity for multi-arm and comparative GHRH analogue studies.
Evidence status: sermorelin acetate was previously marketed in the United States as Geref (FDA approvals in 1990 and 1997). The manufacturer discontinued it in 2008, and the FDA later determined that it was not withdrawn for reasons of safety or effectiveness (Federal Register, 4 March 2013). Those data concern a licensed formulation; they do not describe or verify the research material supplied here.
The research case for sermorelin 5mg research peptide builds on programme scale rather than compound differences. Once Sermorelin 2mg has validated the experimental design and confirmed assay conditions in pilot studies, the 5mg format provides extended single-batch consistency and full dose-response gradient capability across multiple treatment arms. This single-batch consistency is critical when comparing pulse amplitude, pulse frequency, and clearance kinetics across multiple time points where any inter-batch molecular variability would compromise the precision of pulsatile dynamics data.
Sermorelin 5mg is particularly suited to three-analogue GHRH comparison programmes that require equivalent volume across all three compound arms. Running sermorelin 5mg (unmodified) alongside CJC-1295 Without DAC 10mg (four substitutions, including D-Ala2 for DPP-IV resistance) and Tesamorelin 10mg (full 44-amino acid sequence, N-terminal modified) provides a comprehensive structural comparison toolkit.
Ipamorelin 10mg acts at GHS-R1a rather than the GHRH receptor; in whole-animal designs both classes raise GH, so combined arms need appropriate controls. For downstream IGF-1 axis research complementing GHRH studies, IGF-1 LR3 1mg provides the growth factor probe for the downstream signalling cascade.
For the compound’s sequence, GHRH receptor signalling and a side-by-side 2mg vs 5mg comparison, see our Sermorelin research peptide guide.
Independent testing by Janoshik: the published Certificate of Analysis for a tested batch reports measured content and purity. LC-MS identity data is not separately reported on the published certificate. Verifiable CoA.
Prohibited at all times.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
Other laboratory research materials supplied by Ascend Peptides UK.
UK same working-day dispatch – Secure payment options –
Laboratory research only
© 2026 by Ascend Peptides Uk.
All products sold by Ascend Peptides UK are intended strictly for laboratory research purposes only. Not intended for human consumption or therapeutic use of any kind.
Per product, applied automatically in your bagAuto-applied in your bag
Ordering more? Contact us for larger-volume pricing →